A recent example of this is a test for epidermal growth factor receptor (EGFR) mutation in patients with advanced non-small-cell lung cancer, which determines whether or not the first-line EGR tyrosine kinase inhibitor therapy is indicated (Keedy et al. 2011). Here, EGFR is linked to non-small cell lung carcinoma.